Skip to main content

cyclin dependent kinase inhibitor 1C

The CDKN1C gene provides instructions for making a protein that helps regulate growth. This protein acts as a tumour suppressor, which means that it keeps cells from growing and dividing too fast or in an uncontrolled way. It is also active before birth; it regulates growth and prevents the developing fetus from becoming too large.

Video picks for Genes
Video library

Normal function

The CDKN1C gene provides instructions for making a protein that helps regulate growth. This protein acts as a tumour suppressor, which means that it keeps cells from growing and dividing too fast or in an uncontrolled way. It is also active before birth; it regulates growth and prevents the developing fetus from becoming too large.

In most cases, one copy of each gene is derived from the sperm cell and one copy is derived from the egg cell. Both copies are typically active, or "turned on," in cells. However, the activity of the CDKN1C gene differs depending on whether the gene comes from the sperm cell or the egg cell. In most tissues, the copy of the gene that comes from the egg cell is more active than the copy that comes from the sperm cell. This sort of parent-specific difference in gene activation is called genomic imprinting.

A nearby region of DNA undergoes a process called methylation in which small molecules called methyl groups are used to regulate the genomic imprinting of the CDKN1C gene. This region is known as an imprinting center or imprinting control region. In most cases, this imprinting center is methylated only when it comes from the egg cell. 

Conditions referring to this gene or chromosome

Other names

BWCR

KIP2

p57

p57KIP2

Patient picks for Genes

Related patient information and medicines

Pompholyx

Patient information leaflet

Pompholyx

Pompholyx is a type of eczema where there are itchy blisters on the hands and feet, followed by inflamed and dry skin. The condition is usually long-term, with symptoms that come and go at various times. In some cases it has been shown to be helpful for the treatment of pompholyx. Janus Kinase (JAK) inhibitors : these medications, available as.

Mouth cancer

Patient information leaflet

Mouth cancer

Diagnosing mouth cancer Your healthcare professional may suspect mouth cancer if you have a lesion in your mouth (such as a sore, an ... Dr Krishna Vakharia , 16th October 2023 The National Institute for Health and Care Excellence (NICE) has recommended that a person should receive a diagnosis or ruling out of cancer within 28 days of being.

Chronic myeloid leukaemia

Patient information leaflet

Chronic myeloid leukaemia

Chronic myeloid leukaemia (CML) is sometimes called chronic myelogenous leukaemia, chronic granulocytic leukaemia, or chronic myelocytic leukaemia. What is... You may be advised to have one or more of the following treatments: Imatinib tablets. This medicine is known as a tyrosine kinase inhibitor. The chemical tyrosine kinase is made by the.

Mitral regurgitation

Patient information leaflet

Mitral regurgitation

The mitral valve is a heart valve that lies between the left atrium and left ventricle. ...eart - mitral valve incompetence i88_l.jpg What is mitral regurgitationAlthough medicines cannot correct mitral regurgitation, some medicines may be prescribed to help ease symptoms, or to help prevent complications by managing your blood pressure - for.

Mastocytosis and mast cell disorders

Patient information leaflet

Mastocytosis and mast cell disorders

If the condition is severe, surgery to remove the spleen (splenectomy), medicines that have an effect on the immune system (such as interferon), bone marrow transplant or... Dr Sarah Jarvis , 28th September 2021 Midostaurin for treating advanced systemic mastocytosis The National Institute for Health and Care Excellence (NICE) has brought out new.

Myelofibrosis

Patient information leaflet

Myelofibrosis

The gene mutation that occurs in most people affected by myelofibrosis is a mutation in Janus Kinase 2 (JAK2). Dr Sarah Jarvis, December 2021 NICE guidance on drug treatments for myelofibrosis Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis The National Institute for Health and Care Excellence (NICE) has issued.

Further reading and references

Article history

The information on this page is written and peer reviewed by qualified clinicians.
  • 4 Mar 2025 | Latest version
  • 1 Mar 2025 | Originally published

Join the conversation

Share your thoughts or experiences with others in our patient communities.

Disclaimer: The views expressed in the community do not represent medical advice. For any health concerns, consult your GP or healthcare provider.

Online pharmacy, treatments and health services

Simple access to trusted treatments and health services online.

Common conditions

Get help with common conditions through the NHS, without a GP appointment.

Book your free Pharmacy First appointment

Sign up to the Patient newsletter

Your weekly dose of clear, trustworthy health advice - written to help you feel informed, confident and in control.

Please enter a valid email address

By subscribing you accept our Privacy Policy. You can unsubscribe at any time. We never sell your data.